Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

Journal of Hypertension
Ming YuRichard J Roman

Abstract

Dahl salt-sensitive (Dahl S) rats exhibit many phenotypic traits associated with salt-sensitive hypertension in man. Specifically, they are salt-sensitive, insulin-resistant and hyperlipidemic. They also develop endothelial dysfunction, cardiac injury and glomerulosclerosis. Insulin resistance is linked to hypertension, renal and cardiac damage and endothelial dysfunction. Thus, an agent that has diuretic action and can improve insulin resistance, like recombinant glucagon-like peptide-1(7-36)amide (rGLP-1), may have an antihypertensive effect. To determine whether chronic administration of rGLP-1 attenuates the development of hypertension, endothelial dysfunction and/or hypertension-induced renal and cardiac end organ damage in Dahl S rats. Mean arterial pressure (MAP) and urinary excretion of protein and albumin were measured in Dahl S rats before and after they were fed a 8% NaCl diet and infused with rGLP-1 (1 micro g/kg per min, i.v.) or vehicle for 14 days. At the end of the study, the degree of renal and cardiac injury was histologically assessed and endothelium-dependent relaxing function was studied using aortic rings. In other rats, the effects of rGLP-1 on sodium and water balance and plasma glucose and insulin level...Continue Reading

References

Jul 1, 1976·The Journal of Clinical Investigation·R A DeFronzoZ S Agus
May 1, 1992·Hypertension·M Epstein, J R Sowers
Sep 1, 1991·American Journal of Hypertension·E Dall'AglioG M Reaven
Nov 1, 1991·Hypertension·G M ReavenH Chang
Jun 1, 1990·Hypertension·C E GrimD M Wilson
Jun 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W M TierneyF C Luft
Aug 1, 1985·The Journal of Clinical Investigation·S AndersonB M Brenner
Apr 1, 1988·Metabolism: Clinical and Experimental·C E Mondon, G M Reaven
Aug 6, 1987·The New England Journal of Medicine·E FerranniniS Bevilacqua
Jun 1, 1988·Kidney International·R B SterzelW Kriz
Sep 1, 1996·Metabolism: Clinical and Experimental·M ShimabukuroN Takasu
Jan 1, 1997·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M A NauckW Schmiegel
Nov 5, 1997·American Journal of Hypertension·T A KotchenH Y Zhang
Mar 19, 1999·Journal of Internal Medicine·E Ritz
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·A W MillerM R Ujhelyi
Jan 10, 2002·European Journal of Pharmacology·Carol MorenoRichard J Roman

❮ Previous
Next ❯

Citations

May 6, 2014·Reviews in Endocrine & Metabolic Disorders·Jeppe Skov
Sep 17, 2008·The Review of Diabetic Studies : RDS·Richard E Pratley, Matthew Gilbert
Jan 1, 2010·The Review of Diabetic Studies : RDS·Baptist Gallwitz
Jul 22, 2010·European Journal of Human Genetics : EJHG·Virginia BoccardiMichelangela Barbieri
Jul 9, 2011·Cardiovascular Diabetology·Sameer AnsarPeter D Reaven
Jan 10, 2012·Experimental Biology and Medicine·Carrie A NorthcottLaura A Cox
Jun 16, 2012·Indian Journal of Endocrinology and Metabolism·Vishal Gupta
Sep 29, 2012·American Journal of Physiology. Renal Physiology·Scott C ThomsonPrabhleen Singh
Jan 27, 2017·American Journal of Physiology. Renal Physiology·Ravi Nistala, Virginia Savin
Aug 8, 2019·American Journal of Physiology. Renal Physiology·Kenichi KatsuradaKaushik P Patel
Dec 17, 2019·American Journal of Physiology. Renal Physiology·Aleksander Vauvert R Hviid, Charlotte M Sørensen
Dec 15, 2010·Journal of Hypertension·Bruna Pm PachecoAdriana Cc Girardi
Nov 22, 2013·Current Opinion in Nephrology and Hypertension·Karoline von WebskyBerthold Hocher
Feb 14, 2018·Cardiovascular Endocrinology & Metabolism·Josh ReedStephen Bain
Mar 27, 2009·Metabolic Syndrome and Related Disorders·Kevin D LaugeroDavid G Parkes
Dec 19, 2009·American Journal of Hypertension·Ted OkersonRobert Brodows
May 25, 2010·Cellular and Molecular Life Sciences : CMLS·Nikolaus MarxDaniel Walcher
Feb 1, 2011·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Xie Xiao-YunXie Yan-Hong
Jul 16, 2010·Journal of Human Hypertension·A PenesovaZ Radikova
Nov 24, 2011·Diabetes & Metabolism Journal·Ji Sung Yoon, Hyoung Woo Lee
May 2, 2012·Annals of the New York Academy of Sciences·Liza K Phillips, Johannes B Prins
Mar 21, 2012·Herz·M Lehrke, N Marx
Aug 11, 2012·Current Atherosclerosis Reports·Kyung-Sun HeoJun-ichi Abe
Mar 7, 2013·The Journal of Clinical Endocrinology and Metabolism·Jeppe SkovJens Sandahl Christiansen
Aug 31, 2013·Diabetology & Metabolic Syndrome·Asfandyar Sheikh
Jan 29, 2014·Current Hypertension Reports·Akhilesh Rao, Ravi Nistala
Jan 16, 2015·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Abu SufiunAkira Nishiyama
Nov 22, 2014·Current Opinion in Nephrology and Hypertension·Yuichi MakinoMasakazu Haneda
Jun 3, 2015·Current Cardiology Reports·Barbara E StähliJean-Claude Tardif
Mar 25, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·W David Strain, Christine Smith
Apr 6, 2016·Hypertension·Pedro A JoseGilbert M Eisner
Oct 13, 2016·Endocrine Reviews·Gemma Pujadas, Daniel J Drucker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.